Stifel raised the firm’s price target on Oculis (OCS) to $50 from $40 and keeps a Buy rating on the shares after having hosted management on the road. The company approaches pivotal data on OCS-01’s DIAMOND studies in DME, is rapidly advancing privosegtor, and continues the licaminlimab pivotal studies, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Files 2025 Financials and Renews $100 Million ATM Program
- Oculis files automatic mixed securities shelf
- Oculis price target raised to $44 from $42 at H.C. Wainwright
- Oculis: Advancing Late-Stage Ophthalmology Pipeline Drives Upside and Supports Buy Rating
- Oculis: Strengthened Balance Sheet and Advancing Late-Stage Pipeline Support Buy Rating and Higher $40 Target Ahead of 2026 Pivotal Readouts